Identification of an Individualized Metabolism Prognostic Signature and Related Therapy Regimens in Early Stage Lung Adenocarcinoma.
Source check: Source checked. Not independent scientific confirmation.
Finding: The paper reports survival stratification across training, testing and independent cohorts, plus treatment-subgroup analyses and cell assays. Observational treatment-subgroup results do not establish that the signature predicts benefit from a specific therapy.
Technology: Machine learning constructed a 12-gene-pair metabolism risk index and combined it with clinical variables to stratify early-stage lung-adenocarcinoma prognosis.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Machine learning constructed a 12-gene-pair metabolism risk index and combined it with clinical variables to stratify early-stage lung-adenocarcinoma prognosis.
- Test and result
- The paper reports survival stratification across training, testing and independent cohorts, plus treatment-subgroup analyses and cell assays.
- Limitation / still unknown
- Observational treatment-subgroup results do not establish that the signature predicts benefit from a specific therapy.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.650853/full
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.